Press Releases
Filter By Year
September
-
September 25, 2020
European Commission Grants Marketing Authorization for Jyseleca® ▼ (Filgotinib) for the Treatment of Adults With Moderate to Severe Active Rheumatoid Arthritis -
September 25, 2020
Jyseleca® (Filgotinib) Approved in Japan for Rheumatoid Arthritis -
September 24, 2020
Gilead Sciences Prices $7.25 Billion of Senior Unsecured Notes -
September 15, 2020
Gilead’s Magrolimab, an Investigational Anti-CD47 Monoclonal Antibody, Receives FDA Breakthrough Therapy Designation for Treatment of Myelodysplastic Syndrome -
September 13, 2020
Gilead Sciences to Acquire Immunomedics -
September 04, 2020
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Yescarta® in Relapsed or Refractory Indolent Non-Hodgkin Lymphomas -
September 03, 2020
Kite and HiFiBiO Therapeutics Partner to Discover Novel Targets and Antibodies Against Acute Myeloid Leukemia -
September 01, 2020
Gilead Sciences and Jounce Therapeutics Announce Exclusive License Agreement for Novel Immunotherapy Program
August
-
August 28, 2020
Gilead’s Investigational Antiviral Veklury® (Remdesivir) Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of Patients With Moderate COVID-19 -
August 25, 2020
Gilead Announces Presentation of More Than 40 Abstracts From Extensive Liver Disease Programs at the Digital International Liver Congress™ 2020 -
August 18, 2020
Gilead Receives Complete Response Letter for Filgotinib for the Treatment of Moderately to Severely Active Rheumatoid Arthritis -
August 17, 2020
Gilead Sciences and Tango Therapeutics to Expand Strategic Oncology Collaboration -
August 11, 2020
China National Medical Products Administration Approves Truvada® for HIV Pre-Exposure Prophylaxis (PrEP) -
August 10, 2020
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Veklury® (Remdesivir) for the Treatment of COVID-19
July
-
July 30, 2020
Gilead Sciences Announces Third Quarter 2020 Dividend -
July 30, 2020
Gilead Sciences Announces Second Quarter and First Half 2020 Financial Results -
July 28, 2020
Gilead Sciences and Satcher Health Leadership Institute at Morehouse School of Medicine Partner to Study Racial Health Inequities Associated with COVID-19 -
July 24, 2020
U.S. FDA Approves Kite’s Tecartus™, the First and Only CAR T Treatment for Relapsed or Refractory Mantle Cell Lymphoma -
July 24, 2020
Gilead and Galapagos Announce Positive European CHMP Opinion for Jyseleca® (Filgotinib) for the Treatment of Adults With Moderate to Severe Rheumatoid Arthritis -
July 21, 2020
Gilead Sciences Secures Exclusive Option to Acquire Tizona Therapeutics for $300 Million -
July 16, 2020
Gilead Sciences to Release Second Quarter 2020 Financial Results on Thursday, July 30, 2020 -
July 13, 2020
Gilead Sciences and Arcus Biosciences Complete Closing of Their 10-Year Partnership to Co-Develop and Co-Commercialize Next-Generation Cancer Immunotherapies -
July 10, 2020
Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19 -
July 08, 2020
Gilead Sciences Presents Survey Findings on PrEP Access and Utilization in the U.S. During COVID-19 Shelter-in-Place Orders -
July 04, 2020
Gilead Sciences Presents Data Supporting a Potential Six-Month Dosing Interval for Investigational HIV-1 Capsid Inhibitor Lenacapavir (GS-6207) -
July 04, 2020
New Findings on Gilead’s Biktarvy® Presented at AIDS 2020: Virtual Include Positive Switch Data in Older Adults -
July 03, 2020
European Commission Grants Conditional Marketing Authorization for Gilead’s Veklury® (remdesivir) for the Treatment of COVID-19 -
July 01, 2020
Gilead Sciences Demonstrates Commitment to Scientific Innovation In HIV With New Prevention, Treatment and Cure Research Data Presented At AIDS 2020: Virtual
June
-
June 29, 2020
An Open Letter from Daniel O’Day, Chairman & CEO, Gilead Sciences -
June 23, 2020
Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics -
June 16, 2020
Javier Rodriguez Joins Gilead Sciences’ Board of Directors -
June 12, 2020
Kite Receives European Medicines Agency Approval for CAR T Cell Therapy Manufacturing Facility in Europe -
June 05, 2020
New Analyses of Phase 2 EQUATOR Clinical Program Support Durable Efficacy of Filgotinib in Psoriatic Arthritis -
June 04, 2020
Filgotinib Demonstrates Durable Efficacy and Consistent Safety Profile at 52 Weeks in FINCH 1 and 3 Studies in Rheumatoid Arthritis -
June 01, 2020
Mark Genovese Joins Gilead to Lead Clinical Development of Company’s Inflammation Programs -
June 01, 2020
Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19
May
-
May 29, 2020
Investigational Magrolimab in Combination With Azacitidine Demonstrates Durable Activity in Previously-Untreated Myelodysplastic Syndrome and Acute Myeloid Leukemia -
May 29, 2020
Yescarta® (Axicabtagene Ciloleucel) Demonstrates High Rates of Response in Relapsed or Refractory Indolent Non-Hodgkin Lymphoma -
May 27, 2020
Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies -
May 20, 2020
Gilead and Galapagos Announce Positive Topline Results of Phase 2b/3 Trial of Filgotinib in Moderately to Severely Active Ulcerative Colitis -
May 13, 2020
Gilead and Kite Continue to Advance Next Generation Cancer Therapies at 2020 American Society of Clinical Oncology Annual Meeting -
May 07, 2020
Gilead Announces Approval of Veklury® (remdesivir) in Japan for Patients With Severe COVID-19 -
May 01, 2020
Gilead’s Investigational Antiviral Remdesivir Receives U.S. Food and Drug Administration Emergency Use Authorization for the Treatment of COVID-19
April
-
April 30, 2020
Gilead Sciences Announces Second Quarter 2020 Dividend -
April 30, 2020
Gilead Sciences Announces First Quarter 2020 Financial Results -
April 29, 2020
Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19 -
April 29, 2020
Gilead Sciences Statement on Positive Data Emerging From National Institute of Allergy and Infectious Diseases’ Study of Investigational Antiviral Remdesivir for COVID-19 -
April 21, 2020
Gilead, Kite and oNKo-innate Announce Research Collaboration to Discover Cancer Immunotherapies Focused on Natural Killer (NK) Cells -
April 16, 2020
Gilead Sciences to Release First Quarter 2020 Financial Results on Thursday, April 30, 2020 -
April 15, 2020
Gilead Provides Additional Information Regarding 2020 Annual Meeting of Stockholders Due to COVID-19 Precautions -
April 10, 2020
Data on 53 Patients Treated With Investigational Antiviral Remdesivir Through the Compassionate Use Program Published in New England Journal of Medicine -
April 08, 2020
Gilead Announces $20 Million Philanthropic Fund to Support Nonprofit Organizations Impacted by the COVID-19 Crisis -
April 07, 2020
Gilead Completes Acquisition of Forty Seven, Inc. -
April 06, 2020
Gilead Sciences and Second Genome Announce Strategic Collaboration in Biomarker and Inflammatory Bowel Disease Drug Discovery -
April 02, 2020
Kite Licenses Antibodies and Establishes Collaboration With Teneobio in Multiple Myeloma
March
-
March 30, 2020
Gilead Announces Expiration of Hart-Scott-Rodino Waiting Period for Forty Seven Tender Offer -
March 19, 2020
U.S. Food And Drug Administration Approves Epclusa® (Sofosbuvir/Velpatasvir) for Children Ages 6 and Older or Weighing at Least 17 kg with Chronic Hepatitis C Infection -
March 11, 2020
New Clinical Study Data for Gilead’s Investigational HIV-1 Capsid Inhibitor GS-6207 Presented at CROI 2020 -
March 10, 2020
Treatment With Gilead’s Vesatolimod Is Evaluated for Safety and Virologic and Immunologic Response Versus Placebo in Phase 1B HIV Functional Cure Study -
March 10, 2020
Gilead Presents 96-week DISCOVER Trial Data Demonstrating Favorable Renal and Bone Safety Profile of Descovy® for HIV PrEP in At-Risk Populations -
March 09, 2020
New Data on Gilead’s Biktarvy® Presented at CROI 2020, Including Data in Black Americans and Older Adults -
March 02, 2020
Gilead to Acquire Forty Seven for $4.9 Billion
February
-
February 26, 2020
Gilead Sciences Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19 -
February 19, 2020
Gilead Appoints Michael Quigley to Lead Research Biology Group and Names Linda Higgins as Head of Company’s External Innovation Center -
February 19, 2020
Gilead Sciences to Present at the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020 -
February 10, 2020
U.S. FDA Grants Priority Review for Kite’s KTE-X19 Biologics License Application (BLA) in Relapsed or Refractory Mantle Cell Lymphoma -
February 04, 2020
Gilead Sciences Announces 8 Percent Increase In First Quarter 2020 Dividend -
February 04, 2020
Gilead Sciences Announces Fourth Quarter and Full Year 2019 Financial Results
January
-
January 30, 2020
Sandra Horning, MD, Joins Gilead Sciences’ Board of Directors -
January 28, 2020
European Medicines Agency Validates Kite’s Marketing Application for Company’s Second CAR T Cell Therapy -
January 21, 2020
Gilead Sciences to Release Fourth Quarter and Full Year 2019 Financial Results on Tuesday, February 4, 2020 -
January 09, 2020
Gilead Sciences Licenses Portfolio of HIV Antibodies From The Rockefeller University
Filter By Year